AstraZeneca: data encouraging for Lynparza

© Reuters. AstraZeneca: data encouraging for Lynparza

AstraZeneca (LON:AZN) and Merck (NYSE:MRK) revealed encouraging data regarding their Lynparza in metastatic breast cancer, on the occasion of the annual meeting of the American Association for Cancer Research (AACR) in Chicago.

The two pharmaceutical groups report that in a phase III trial, their drug has achieved its primary goal of progression-free survival, with a median of 19.3 months compared to 17.1 months for patients treated with chemotherapy.

Copyright (c) 2018 All rights reserved.

Like this post? Please share to your friends:
Leave a Reply